摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-fluoro-N-(2-fluoro-4-(((R)-3-methylmorpholino)methyl)phenyl)-4-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl)pyrimidin-2-amine hydrochloride | 1252575-61-3

中文名称
——
中文别名
——
英文名称
5-fluoro-N-(2-fluoro-4-(((R)-3-methylmorpholino)methyl)phenyl)-4-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl)pyrimidin-2-amine hydrochloride
英文别名
5-fluoro-N-[2-fluoro-4-[[(3R)-3-methylmorpholin-4-yl]methyl]phenyl]-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine;hydrochloride
5-fluoro-N-(2-fluoro-4-(((R)-3-methylmorpholino)methyl)phenyl)-4-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl)pyrimidin-2-amine hydrochloride化学式
CAS
1252575-61-3
化学式
C25H30F2N6O2*ClH
mdl
——
分子量
521.01
InChiKey
KDVUZQGENDKDNO-PKLMIRHRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.66
  • 重原子数:
    36
  • 可旋转键数:
    6
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.48
  • 拓扑面积:
    77.3
  • 氢给体数:
    2
  • 氢受体数:
    9

反应信息

  • 作为产物:
    描述:
    5-氟-4-[2-甲基-1-(四氢-2H-吡喃-4-基)-1H-咪唑-5-基]-2-嘧啶胺 、 (R)-4-(4-bromo-3-fluorobenzyl)-3-methylmorpholinetris-(dibenzylideneacetone)dipalladium(0) 盐酸氢氧化钾potassium tert-butylate 作用下, 以 1,4-二氧六环二氯甲烷N,N-二甲基甲酰胺 为溶剂, 以10%的产率得到5-fluoro-N-(2-fluoro-4-(((R)-3-methylmorpholino)methyl)phenyl)-4-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl)pyrimidin-2-amine hydrochloride
    参考文献:
    名称:
    Imidazole Substituted Pyrimidines
    摘要:
    式(I)的化合物,其中R1为氢或氟;R2和R3分别选择自氢或甲基,或其药用可接受的盐;含有该化合物的药物配方;该化合物在治疗中的使用;用于治疗与糖原合酶激酶-3相关疾病的条件,如阿尔茨海默病,以及治疗上述疾病的方法,包括向需要该治疗的受试者施用该化合物的治疗有效量。
    公开号:
    US20100267723A1
点击查看最新优质反应信息

文献信息

  • Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease
    申请人:Burrows Jeremy Nicholas
    公开号:US20120077813A1
    公开(公告)日:2012-03-29
    The present invention relates to a new compound of formula (I) wherein R 1 is hydrogen or fluoro; R 2 and R 3 are independently selected from hydrogen or methyl; or a pharmaceutically acceptable salt thereof, pharmaceutical formulations containing said compound, to the use of said active compound in therapy, to the use for the treatment of conditions associated with glycogen synthase kinase-3 related disorders, such as Alzheimer's disease, as well as for the method of treatment of said disorders, comprising administering to a mammal, including human in need of such treatment, a therapeutically effective amount of said compound.
    本发明涉及一种新的化合物,其化学式为(I),其中R1是氢或氟;R2和R3分别选择氢或甲基;或其药学上可接受的盐,含有该化合物的制药配方,以及将该活性化合物用于治疗的用途,用于治疗与糖原合成酶激酶-3相关疾病有关的疾病,例如阿尔茨海默病,以及治疗该疾病的方法,包括向需要此类治疗的哺乳动物,包括人类,给予该化合物的治疗有效量。
  • IMIDAZOLE SUBSTITUTED PYRIMIDINES USEFUL IN THE TREATMENT OF GLYCOGEN SYNTHASE KINASE 3 RELATED DISORDERS SUCH AS ALZHEIMER'S DISEASE
    申请人:AstraZeneca AB
    公开号:EP2419425A1
    公开(公告)日:2012-02-22
  • US8178529B2
    申请人:——
    公开号:US8178529B2
    公开(公告)日:2012-05-15
  • [EN] IMIDAZOLE SUBSTITUTED PYRIMIDINES USEFUL IN THE TREATMENT OF GLYCOGEN SYNTHASE KINASE 3 RELATED DISORDERS SUCH AS ALZHEIMER'S DISEASE<br/>[FR] PYRIMIDINES SUBSTITUÉES PAR IMIDAZOLE UTILES DANS LE TRAITEMENT DE TROUBLES LIÉS À LA GLYCOGÈNE SYNTHASE KINASE 3, TELS QUE LA MALADIE D'ALZHEIMER
    申请人:ASTRAZENECA AB
    公开号:WO2010120237A1
    公开(公告)日:2010-10-21
    The present invention relates to a new compound of formula (I) wherein R1 is hydrogen or fluoro; R2 and R3 are independently selected from hydrogen or methyl; or a pharmaceutically acceptable salt thereof, pharmaceutical formulations containing said compound, to the use of said active compound in therapy, to the use for the treatment of conditions associated with glycogen synthase kinase-3 related disorders, such as Alzheimer's disease, as well as for the method of treatment of said disorders, comprising administering to a mammal, including human in need of such treatment, a therapeutically effective amount of said compound.
  • Imidazole Substituted Pyrimidines
    申请人:Arvidsson Per I
    公开号:US20100267723A1
    公开(公告)日:2010-10-21
    A compound of formula (I) wherein R 1 is hydrogen or fluoro; R 2 and R 3 are independently selected from hydrogen or methyl, or a pharmaceutically acceptable salt thereof; pharmaceutical formulations containing said compound; the use of said compound in therapy; the use for the treatment of conditions associated with glycogen synthase kinase-3 related disorders, such as Alzheimer's disease, as well as methods of treatment of said disorders, comprising administering to subjects in need of such treatment, a therapeutically effective amount of said compound.
    式(I)的化合物,其中R1为氢或氟;R2和R3分别选择自氢或甲基,或其药用可接受的盐;含有该化合物的药物配方;该化合物在治疗中的使用;用于治疗与糖原合酶激酶-3相关疾病的条件,如阿尔茨海默病,以及治疗上述疾病的方法,包括向需要该治疗的受试者施用该化合物的治疗有效量。
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺